Immunic, INC DEF 14A proxy statements

Immunic, Inc. announces the appointment of Erik Lundgren as CEO and seeks shareholder approval to increase its 2019 Omnibus Equity Incentive Plan by 6 million shares.

Immunic, Inc. is calling a special meeting on April 14, 2026, to seek stockholder approval for a reverse stock split to maintain its Nasdaq listing and facilitate future capital raising.

Immunic, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Immunic, Inc. is holding its annual stockholder meeting on June 4, 2025, to vote on the election of Class II directors, an amendment to the 2019 Omnibus Equity Incentive Plan, and the ratification of its independent auditor.

Immunic, Inc. will hold its annual stockholders meeting virtually on June 11, 2024, to vote on the election of directors, ratification of the independent accounting firm, and executive compensation.